Samsung heir dodges jail over controversial merger

  • 📰 fmtoday
  • ⏱ Reading Time:
  • 49 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 72%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Lee Jae-yong has effectively been at the helm since his father suffered a heart attack in 2014. FMTNews

SEOUL: A South Korean court on Tuesday declined to issue an arrest warrant for the heir to South Korea’s Samsung empire over a controversial merger of two business units seen as a key step to his succession, Yonhap news agency reported.

Prosecutors had sought the arrest warrant for Lee on suspicion he was involved in price manipulation and illegal trading during the 2015 merger of Cheil Industries and Samsung C&T. “There was insufficient explanation on the need to arrest the defendants against the principle of trial without detention,” Judge Won Jung-sook said, according to Yonhap.

Chaebol families often have only a small ownership stake in their empires, but maintain control through complex webs of cross-shareholdings between units.Lee was the largest shareholder in Cheil Industries, and critics say Samsung sought to artificially lower the price of C&T to give him a bigger stake in the merged entity – a key part of the Samsung structure – consolidating his grip on the conglomerate.

Lee, 51, has effectively been at the helm of Samsung – South Korea’s biggest business group – since his father and Samsung group boss Lee Kun-hee suffered a heart attack in 2014.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 5. in BR

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Report: Astra eyes record merger with drug rival Gilead | Malay MailLONDON, June 8 — British pharmaceuticals group AstraZeneca has approached US rival Gilead Sciences over a possible record merger, Bloomberg reported, as the pair spearhead treatments for Covid-19. AstraZeneca informally contacted Gilead last month, yesterday’s report said, adding that a...
Fonte: malaymail - 🏆 1. / 86 Consulte Mais informação »